IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
Patients with metastatic or recurrent and refractory sarcomas have a dismal prognosis. Therefore, new targeted therapies are urgently needed. This study was designed to evaluate chimeric antigen receptor (CAR) T cells targeting the type I insulin-like growth factor receptor (IGF1R) or tyrosine kinas...
Main Authors: | Xin Huang, Haein Park, Joseph Greene, James Pao, Erin Mulvey, Sophia X Zhou, Catherine M Albert, Fred Moy, Deepali Sachdev, Douglas Yee, Christoph Rader, Carl V Hamby, David M Loeb, Mitchell S Cairo, Xianzheng Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4501840?pdf=render |
Similar Items
-
Anti-ROR1 CAR-T cells: Architecture and performance
by: Daniel Andrés Osorio-Rodríguez, et al.
Published: (2023-02-01) -
ROR1 and ROR2 expression in pancreatic cancer
by: Dongli Liu, et al.
Published: (2021-11-01) -
Immunoprecipitation of ROR1
by: Vincent Bicocca, et al.
Published: (2013-09-01) -
Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein
by: Jie Xian, et al.
Published: (2024-07-01) -
ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
by: Guilly eRebagay, et al.
Published: (2012-04-01)